ClinicalTrials.gg
RecruitingNCT06145893Updated Apr 8, 2025

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

A Phase 3 interventional study of Hemay005 and Hemay005 in Behçet's Disease, sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Recruiting at 22 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Behcet Syndrome with a site in China — 7 open to participants now, 7 under way, 1 of them phase 3. Behcet Syndrome · China.

Planned enrollment
Largest of 13
162 · median 50
Started
2023
with 2 others
Phase 3
2 of 16
1 open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Ganzhou Hemay Pharmaceutical Co., Ltd

Among the 16 studies in Behcet Syndrome with a site in China, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 3, and was the 10th registered.

Behcet Syndrome

136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.

Browse Behcet Syndrome studies →

Open to participants now

7 of the 16 studies in Behcet Syndrome with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Behcet Syndrome with a site in China, or all of them as a file.
02

Study summary

This is a phase 3, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 40 weeks and a follow up phase for 4weeks.

Read the detailed description

This is a multi-center, randomized, double-blind, placebo-parallel controlled phase III clinical study. The study consists of four phases, namely the screening period, the core treatment period, the extension period, and the drug discontinuation observation period.

Screening period: All subjects will undergo a screening period for up to 8 weeks prior to the baseline visit (V2, randomization day, Day 0).

Core treatment period: Patients with Behçet's disease (BD) meeting the eligibility criteria upon screening will be randomized in a 1:1: 1 ratio to the Hemay005 Tablets 45 mg BID test group, Hemay005 Tablets 60 mg BID test group, or the placebo group. They will first be given escalating doses for 7 days; subsequently starting from Day 7, they will be given Hemay005 Tablets 45 mg BID or 60 mg BID or the placebo BID continuously until Week 12.

Extension period: Considering benefits for subjects in the placebo group, and to observe the efficacy and safety of long-term treatment, all subjects will enter a 40-week extension period at the end of the core treatment period. Subjects enrolled in the test groups for the core treatment period will continue treatment at the dose for the core treatment period for 40 weeks during the extension period. Subjects enrolled in the placebo group for the core treatment period will be randomized in a 1:1 ratio during the extension period to either the Hemay005 Tablets 45 mg BID test group or Hemay005 Tablets 60 mg BID test group for treatment for 40 weeks. For the first week of extended treatment, subjects previously enrolled in the placebo group will need to undergo the same dose titration phase as for the core treatment period (Days 0-6), so that the same dosing schedule as for the two treatment groups would be achieved by the 7th day, in an effort to mitigate the intolerabilities such as gastrointestinal reactions, thus further protecting subjects' safety. If, during the dose titration phase of the extension period or during extended treatment, the subject cannot tolerate the prescribed dose, this will be handled at the investigator's discretion using the same method as for the core treatment period.

Drug discontinuation observation period: All subjects in the study (including those who prematurely discontinued treatment for any reason) will be observed for 4 weeks following the end of the last study dose.

03

Conditions studied

  • Behçet's Disease

Browse trials for

Keywords

  • Behçet's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understanding and voluntarily signing the Form (ICF) for this study;
  2. Age 18-75 years (inclusive), male or female;
  3. Diagnosed as BD based on the ICBD-2013;
  4. At least 2 oral ulcers present at V1 (screening), and:

    1. at least 2 oral ulcers present at V2 (the day of randomization) when V2 occurs 14-56 days after V1; OR
    2. at least 3 oral ulcers present at V2 (the day of randomization) when V2 occurs 0-13 days after V1;
  5. Applicability of systemic treatment for oral ulcers: Based on the severity of the disease and the involved area, the investigator determines that the patient's oral ulceration is not suitable for topical treatment or that the patient's oral ulceration cannot be effectively controlled by topical treatment, so that systemic treatment is to be used;
  6. Throughout the study period from signing of ICF through 3 months after the last study dose, women of and male subjects who have not undergone vasoligation should use effective measures, including vasoligation, abstinence, intrauterine device (IUD), hormones (oral, patches, rings, injections, implants) and barrier methods (diaphragms, cervical caps, sponges, condoms);
  7. Being able to comply with the follow-up schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Active lesions associated with BD in major organs requiring treatment, e.g., those in lungs (e.g., pulmonary aneurysm), blood vessels (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal tract (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis); Note: Patients with BD who experienced gastrointestinal perforation, active bleeding, or obstruction, etc. within 3 months prior to randomization are to be excluded.
  2. Any heart disease (including but not limited to: unstable ischemic heart disease, III/IV left ventricular failure, or myocardial infarction) or clinically significant 12-lead abnormalities detected during the 6 months prior to screening, which, at the investigator's discretion, may put the subject at safety risk or may interfere with the study assessments;
  3. Use of the following immunomodulatory therapies:

    • Colchicine within 7 days prior to randomization;
    • Perazathioprine, mycophenolate, baritinib, or tofacitinib within 10 days prior to randomization;
    • Cyclosporine, methotrexate, cyclophosphamide, thalidomide, or dapsone within 4 weeks (28 days) prior to randomization;
    • Biologics within 5 half-lives prior to randomization, e.g.:

      • Etanercept within 4 weeks prior to randomization;
      • Infliximab or leflunomide within 8 weeks prior to randomization;
      • Adalimumab, golimumab, abatacept, or tolizumab within 10 weeks prior to randomization;
      • Secukinumab within 6 months prior to randomization;
  4. Intraarticular or systemic treatment prior to randomization and within 5 pharmacokinetic/pharmacodynamic half-lives; Note: For subjects with eye symptoms, glucocorticoid eye drops are allowed throughout the trial (except for within 24 hours prior to a trial visit).
  5. Chinese patent medicines with immunomodulatory effect within 2 weeks prior to randomization; any Chinese pate nt medicines or decoctions within 2 weeks prior to randomization that might affect efficacy evaluation, or containing sinomenine, total glucoside of paeony, or tripterygium wilfordii, etc.;
  6. Laboratory tests:

    • ≤85g/L;
    • White blood cell count \<3.0×10\^9/L or >14×10\^9/L;
    • \<100×10\^9/L;
    • Serum creatinine >1.5 mg/dL (>132.6 μmol/L);
    • Total of >2.0 mg/dL (>34.2 μmol/L);
    • Both (AST) and alanine aminotransferase (ALT) ≥1.5×; Note: The above tests can be repeated at most once during the screening period. If the result within 2 weeks prior to randomization falls into the specified range, the subject is eligible for the study;
  7. Use of potent inducers of cytochrome P450 enzymes (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin sodium) within 4 weeks prior to randomization;
  8. Other diseases or chronic inflammatory diseases associated with immunity, e.g., rheumatic fever, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, multiple sclerosis, Sjögren's syndrome, and inflammatory bowel disease;
  9. Currently active infections or recurrent bacterial, fungal, viral, mycobacterial or other infectious diseases (including but not limited to tuberculosis, atypical mycobacteriosis, , , herpes zoster, histoplasmosis, and coccidiosis; however, onychomycosis is excluded), which, at the investigator's discretion, may put the subject at safety risk; Note: Subjects positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, or with a history of active mycobacterial infection of any species (including Mycobacterium tuberculosis) within 3 years prior to screening visit should be excluded. Screening is permitted if the subject has been cured for at least 3 years prior to randomization with documentation available for verification;
  10. Clinically significant chest X-ray or CT abnormalities, which, at the investigator's discretion, may put the subject at safety risk; Note: If a chest X-ray or CT was performed within 3 months prior to V1, the examination may be omitted for V1;
  11. History of transplantation or immunodeficiency;
  12. Positive for (HIV) antibody or treponema pallidum antibody test;
  13. Currently having a malignant tumor, or a history of any malignant tumor within 5 years prior to screening (except for treatment-experienced squamous cell carcinoma in situ of the skin, basal cell carcinoma or cervical carcinoma in situ with no evidence of relapse within the past 12 months);
  14. Use of any clinical product within 4 weeks prior to randomization or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer; Note: Subjects who have participated in HM005BD2S01 study are not eligible to participate in this trial;
  15. Known allergy to the study drug or any of its components or allergic constitution;
  16. A history of alcohol or drug abuse or dependence, or psychiatric disorder;
  17. Any conditions that may interfere with oral drug absorption, e.g., subtotal gastrectomy, clinically significant diabetic gastrointestinal disease, or certain types of bariatric surgery such as gastric bypass surgery, not including procedures that simply separate the stomach into separate chambers such as gastric banding surgery;
  18. Prior use of apremilast;
  19. Female subjects who are pregnant or breast feeding;
  20. Concomitant serious, progressive, or uncontrolled diseases, with which participation in the study may, at the investigator's discretion, put the subject at potential risk or affect the interpretation of study results.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Hemay005 high dose group

    In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 40 weeks.

    Drug: Hemay005

  • Experimental
    Hemay005 lower dose group

    In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 40 weeks.

    Drug: Hemay005

  • Placebo comparator
    Placebo

    In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 40 weeks.

    Drug: Placebo

Interventions

  • Hemay005 tables 60mg bid p.o;

    Also known as: Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors

  • Hemay005 tables 45mg bid p.o;

    Also known as: Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors

  • DrugPlacebo

    placebo to Hemay005 tables bid p.o

06

What researchers measure

Primary outcomes

  1. Efficacy assessed by oral ulcers

    Area under the curve (AUC) of the number of oral ulcers in BD patients from baseline to Week 12

    Time frame: week 12

Secondary outcomes

  1. efficacy assessed by oral ulcers

    Complete response rate for oral ulcers at Week 12,22,32,42,52; A complete response is defined as the proportion of subjects who are oral ulcer free

    Time frame: week 12, 22, 32, 42, 52

  2. pain of oral ulcers assessed by VAS

    Change from baseline in the pain of oral ulcers as measured by VAS at Week 12,22,32,42,52

    Time frame: week 12, 22, 32, 42, 52

  3. efficacy assessed by genital ulcers

    Complete response rate for genital ulcers at Week 12,22,32,42,52 for subjects who had genital ulcers at Baseline; A complete response is defined as the proportion of subjects who are genital ulcer-free

    Time frame: week 12, 22, 32, 42, 52

  4. pain of genital ulcers assessed by VAS

    Change from baseline in the pain of genital ulcers, as measured by VAS at Week 12,22,32,42,52 in subjects who had genital ulcers at baseline

    Time frame: week 12, 22, 32, 42, 52

  5. efficacy assessed by BDCAF

    Change from baseline in disease activity as measured by Behçet's Disease Current Activity scores (BD Current Activity Form) at Week 12,22,32,42,52

    Time frame: week 12, 22, 32, 42, 52

  6. efficacy assessed by BSAS

    Change from Baseline in Behçet's Syndrome Activity Score (BSAS) at Week 12,22,32,42,52

    Time frame: week 12, 22, 32, 42, 52

  7. efficacy assessed by oral ulcers

    Time to oral ulcer resolution (complete response), ie, the first instance when a subject has a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  8. efficacy assessed by oral ulcers

    Proportion of subjects with no oral ulcers following complete response, ie, the first time when a subject has a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  9. efficacy assessed by oral ulcers

    Number of oral ulcers following loss of complete response, ie, the first instance when a subject has a reappearance of oral ulcers following a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  10. efficacy assessed by oral ulcers

    Time to recurrence of oral ulcers following loss of complete response, ie, the first instance when a subject has a reappearance of oral ulcers following a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  11. efficacy of skin lesions assessed by PGA score

    Change from baseline in the total score of the Static Physician's Global Assessment (PGA) of skin lesions (acne-like lesions, folliculitis and erythema nodosum) of BD at Week 12,22,32,42,52 in subjects who had BD skin lesions at baseline

    Time frame: week 12, 22, 32, 42, 52

  12. efficacy assessed by oral ulcers

    Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) by Week 6, after start of dosing, and who remain oral ulcer free for at least 6 additional weeks during the 12-week Placebo-controlled Treatment Phase

    Time frame: week 2, 4, 6, 8, 10, 12

  13. Quality of life measured by BD QoL

    Change from baseline in the BD QoL score at Week 12,22,32,42,52

    Time frame: week 12, 22, 32, 42, 52

  14. Quality of life measured by SF-36

    Change from baseline in SF-36 score at Week 12, 22,32,42,52

    Time frame: week 12, 22, 32, 42, 52

  15. efficacy assessed by tender and/or swollen joints

    Change from baseline in number of tender and/or swollen joints associated with BD at Week 12,22, 32, 42, and 52 in subjects who had BD-related tender and/or swollen joints at baseline;

    Time frame: week 12, 22, 32, 42, 52

  16. efficacy assessed by gastrointestinal activity

    Changes from baseline in Disease Activity Index for Intestinal Behçet's Disease (DAIBD) score at Weeks 12, 22, 32, 42, and 52

    Time frame: week 12, 22, 32, 42, 52

  17. efficacy assessed by gastrointestinal symptoms

    Changes from baseline in Global GI symptoms assessment at Weeks 12 and 52

    Time frame: week 1, 12, 52

  18. efficacy assessed by biomarkers.

    Changes from baseline in CRP and ESR at Weeks 12, 22, 32, 42, and 52;

    Time frame: week 12, 22, 32, 42, 52

  19. efficacy assessed by eye symptoms.

    Changes from baseline in best corrected visual acuity (BCVA) at Weeks 12, 22, 32, 42, and 52, and changes from baseline in improvement of inflammation (slit lamp and/or ophthalmoscopy/fundus photography optical coherence tomography (OCT), etc.) at Weeks 12 and 52

    Time frame: week 12, 22, 32, 42, 52

  20. population pharmacokinetics (PopPK)

    Area under the curve (AUC)

    Time frame: week 4, 12

  21. population pharmacokinetics (PopPK)

    Maximum Plasma Concentration (Cmax)

    Time frame: week 4, 12

  22. population pharmacokinetics (PopPK)

    Minimum Plasma Concentration (Cmin)

    Time frame: week 4, 12

  23. population pharmacokinetics (PopPK)

    Time to peak (Tmax)

    Time frame: week 4, 12

  24. population pharmacokinetics (PopPK)

    Elimination half-life (T1/2)

    Time frame: week 4, 12

  25. population pharmacokinetics (PopPK)

    Clearance (Cl)

    Time frame: week 4, 12

  26. safety assessed by Type, frequency, severity and relationship with drug of AEs

    Type, frequency, severity and relationship with Hemay005 of AEs

    Time frame: week 1, 2, 4, 6, 8, 10, 12, 22, 32, 43, 52, 56

  27. safety and tolerability assessed by discontinuation due to AEs

    Number of subjects prematurely discontinuing the investigational product due to AE

    Time frame: week 1, 2, 4, 6, 8, 10, 12, 22, 32, 43, 52, 56

  28. safety and feasibility assessed by lab examinations

    Frequency of clinically significant changes in vital signs, weight, laboratory findings, physical examination, and/or 12-lead ECG

    Time frame: week 1, 2, 4, 6, 8, 10, 12, 22, 32, 43, 52, 56

Other outcomes

  1. efficacy assessed by oral and genital ulcers

    The AUC for the combined number of oral and genital ulcers from baseline through Week 12

    Time frame: week 12

  2. efficacy assessed by genital ulcers

    Time to genital ulcer complete response, ie, the first instance when a subject has a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  3. efficacy assessed by genital ulcers

    Proportion of subjects with no genital ulcers following complete response, ie, the first time when a subject has a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

  4. efficacy assessed by genital ulcers

    Number of genital ulcers following loss of complete response ie, the first instance when a subject has a reappearance of oral ulcers following a complete response, during the Placebo-controlled Treatment Phase

    Time frame: week 1, 2, 4, 6, 8, 10, 12

07

Study locations

19 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for May 2026, 30 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2023
First posted
Nov 24, 2023
StartActual
Nov 13, 2023
Primary completionEst.
May 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06145893
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Nov 24, 2023
Start date
Nov 13, 2023
Primary completion
May 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Apr 8, 2025

Study contacts

Jinfeng Lin
Contact
linjinfeng@hemay.com.cn
15790249669
Zhanguo Li, Doctor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion